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Abstract
Background: Neisseria gonorrhoeae strains with resistance to extended-spectrum cephalosporins (ESCs), last options
for first-line monotherapy of gonorrhoea, likely emerged and initially disseminated in Japan, followed by
international transmission. In recent years, multi-locus sequence typing (MLST) ST1901 and N. gonorrhoeae
multiantigen sequence typing (NG-MAST) ST1407 isolates with the mosaic penicillin-binding protein (PBP) 2 XXXIV
have accounted for most ESC resistance globally. Our aim was to elucidate the initial emergence and transmission
of ESC-resistant strains by detailed examination of N. gonorrhoeae isolates from 1995 to 2005 in Kanagawa, Japan.
Methods: N. gonorrhoeae isolates were examined phenotypically (n = 690) and genetically (n = 372) by agar dilution
method (cefixime, ceftriaxone and ciprofloxacin), penA gene sequencing, MLST and NG-MAST.
Results: Already in 1995, one cefixime-resistant (CFM-R) isolate was found, which is the first CFM-R isolate described
globally. After 1996, the prevalence of CFM-R and CFM-decreased susceptibility (CFM-DS) isolates significantly
increased, with the peak resistance level in 2002 (57.1 % CFM-R). In 1997–2002, the CFM-R MLST ST7363 strain type
with the mosaic PBP 2 X was predominant among CFM-R/DS isolates. The first CFM-R/DS MLST ST1901 clone(s),
which became the predominant CFM-R/DS strain type(s) already in 2003–2005, possessed the mosaic PBP 2 X,
which was possibly originally transferred from the MLST ST7363 strains, and subsequently acquired the mosaic PBP
2 XXXIV. The first MLST ST1901 and NG-MAST ST1407 isolate was identified in Kanagawa already in 2003.
Conclusions: The two main internationally spread cefixime-resistant gonococcal clones, MLST ST7363 and ST1901
(NG-MAST ST1407 most frequent internationally) that also have shown their capacity to develop high-level
ceftriaxone resistance (superbugs H041 and F89), likely emerged, evolved and started to disseminate in the
metropolitan area, including Kanagawa, in Japan, which was followed by global transmission.
Background
Gonorrhoea, aetiological agent Neisseria gonorrhoeae, is a
major public health concern worldwide, and in 2008 the
World Health Organization (WHO) estimated 106 million
new cases among adults globally [1]. Since the introduction
of antimicrobials for treatment of gonorrhoea in the mid-
1930s, N. gonorrhoeae has developed resistance to all previ-
ously used first-line antimicrobials for empirical treatment
of gonorrhoea. In many countries, the extended-spectrum
cephalosporins (ESCs) are the only remaining options for
empirical antimicrobial monotherapy [2–7]. Disquietingly,
treatment failures with cefixime (CFM) have been reported
in several countries [3, 8, 9], and rare cases of treatment
failures with the more potent ceftriaxone (CRO) have been
verified in a few countries [3, 7, 10–12]. Most of these ESC
treatment failures have been caused by multidrug resistant
(MDR) N. gonorrhoeae strains belonging to the multi-locus
sequence typing (MLST) sequence types (ST) ST7363 and
ST1901 [3, 4, 7, 9, 12, 13]. Among the ESC-resistant MLST
ST1901 gonococcal strains, isolates assigned to the N.
gonorrhoeae multiantigen sequence typing (NG-MAST)
ST1407 have been the most frequent [3, 4, 8, 9, 12]. Fur-
thermore, MLST ST7363 (NG-MAST ST4220) and MLST
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ST1901 (NG-MAST ST1407) strains have also shown their
capacity to develop high-level in vitro resistance to CRO.
These types of strains, which has been referred to as
“superbugs”, were isolated in Japan (“H041”), France
(“F89”) and Spain (“F89”) from 2009 to 2011 [7, 14, 15],
which might represent the initial phase of dissemination of
gonococcal strains with high-level CRO resistance. The
main ESC-resistance mechanism in these high-level CRO-
resistant gonococcal isolates was novel mosaic penA gene
alleles, encoding the ESC-target penicillin-binding protein
2 (PBP 2) [3, 7, 14, 15]. ESC-resistant MLST ST7363 and
ST1901 N. gonorrhoeae strains have been frequently
associated with the mosaic PBP 2 X and XXXIV, re-
spectively [3, 4, 7, 9, 12, 13].
Over the past two decades, gonococcal strains with de-
creased susceptibility and resistance to ESCs have been
suspected to have emerged in Japan and subsequently
spread internationally [2–4]. For example, from 1995 to
2000, in Fukuoka, Japan, the MIC peak of CFM and
CRO in gonococcal isolates increased from 0.008 mg/L
to 0.25 mg/L and from 0.015 mg/L to 0.064 mg/L, re-
spectively [16]. Furthermore, from 1999 to 2002 in six
hospitals in central Japan, the proportion of gonococcal
isolates with decreased susceptibility or resistance to
CFM (MIC ≥ 0.5 mg/L) and CRO (MIC ≥ 0.5 mg/L) in-
creased from 0 % to 30.2 % and from 0 % to 0.9 %, re-
spectively [17]. The first treatment failures with CFM
were also described in Japan, i.e. in the late 1990s and
early 2000s [18, 19]. Accordingly, already in the late
1990s ESC-resistant N. gonorrhoeae strains emerged and
were disseminated in Japan. However, the genetic re-
latedness between the ESC-resistant N. gonorrhoeae
strains spreading in Japan 1–2 decades ago and the ESC-
resistant gonococcal strains currently spreading inter-
nationally has not been investigated appropriately. It is
crucial to understand the emergence and spread of ESC-
and MDR-resistant gonococcal strains globally in order
to develop and implement evidence-based strategies for
prevention and control of gonorrhoea.
The aim of this study was to examine 690 (372 genet-
ically) N. gonorrhoeae isolates cultured from 1995 to
2005 in Japan (the initial phase of emergence and dis-
semination of ESC-resistant strains) using antimicrobial




In total, 690N. gonorrhoeae isolates, cultured at the
Kanagawa Prefectural Institute of Public Health, Japan
from 1995 to 2005, were included. N. gonorrhoeae isolates
were cultured, species identified and stored as described
previously [20, 21]. All examined gonococcal isolates were
cultured and preserved as part of the routine diagnostics
(standard care) and no patient identification information
was available in the present study. Accordingly, ethical ap-
proval was not required for this study.
Antimicrobial susceptibility testing
The MICs (mg/L) of CFM, CRO and ciprofloxacin were
determined for all isolates immediately after initial isola-
tion by the agar dilution method, according to the in-
structions from the Clinical and Laboratory Standards
Institute (CLSI) [22]. However, the MIC values for all
the isolates with resistance (R) or decreased susceptibil-
ity (DS) to CFM (CFM-R/DS) were also verified in the
present study by repeated testing using the identical agar
dilution method. The resistance breakpoints stated by
the European Committee on Antimicrobial Susceptibility
Testing (EUCAST; www.eucast.org) were applied. How-
ever, additionally CFM-DS and CRO-DS was defined as
MIC = 0.125 mg/L, because treatment failures with both
CFM and CRO have been caused by gonococcal isolates
with this MIC [3, 8, 10–12]. The N. gonorrhoeae inter-
national reference strains WHO A, B and E were used
for quality control.
DNA extraction
The bacterial isolates were suspended in TE buffer
(10 mM Tris, 1 mM EDTA, pH 8.0) and boiled for 10 min.
After centrifugation to remove cell debris, the supernatant
was promptly used as DNA template for the PCRs.
penA gene sequencing
The penA gene was PCR amplified and sequenced using
the previously described primers penA_F and penA_R
[13]. Briefly, the PCR mixtures were incubated for 2 min
at 96 °C, followed by 30 cycles of 10 s at 96 °C, 10 s at
65 °C and 2 min at 72 °C. The PCR products were sub-
sequently purified with the ExoSAP IT kit (GE Health-
care Limited, Buckinghamshire, United Kingdom). Both
DNA strands of the PCR products were sequenced with
an ABI BigDye Terminator cycle sequencing kit (version
3.1) on an ABI 3130 xl sequencer, in accordance with
the instructions from the manufacturer (Applied Biosys-
tems, Foster City, CA, USA). The penA gene that en-
codes the PBP 2 X sequence variant has a mosaic-like
structure that includes regions relatively similar to the
corresponding regions of the penA genes of N. perflava,
N. sicca and N. cinerea [23]. Subsequently, many differ-
ent mosaic PBP 2 sequences have been described, which
have up to 60 to 70 amino acid changes compared to a
wild type PBP 2 sequence [7]. In the present study, all
these sequences are named as mosaic PBP 2 sequence
variants and wild type PBP 2 (e.g., GenBank accession
no. M32091) and highly similar sequences are defined as
non-mosaic PBP 2 sequences.
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The nucleotide sequences of penA determined in the
present study have been deposited in the DDBJ sequence
library and assigned the accession numbers LC055782
and LC055783.
Molecular epidemiological characterisation
Molecular epidemiological characterisation by means of
MLST (based on partial alleles of seven loci, abcZ, adk,
aroE, fumC, gdh, pdhC and pgm) and NG-MAST (based
on partial alleles of porB and tbpB) was performed as de-
scribed elsewhere [24]. New alleles (and STs) identified
in this study were named and deposited in the MLST
and NG-MAST database, respectively (Tables 1 and 2).
The diversity index for the MLST and NG-MAST was
calculated as described earlier [24]. UPGMA trees based
on partial porB gene sequences (490 bp), i.e. obtained in
the NG-MAST, were generated using the MEGA 4
software.
Statistical analysis
The distribution of MLST ST7363 in CFM-S and CFM-
R/DS strains was analysed by Fisher’s exact test.
Results
Emergence of cephalosporin resistance in Neisseria
gonorrhoeae in Japan
Already in 1995, among 34N. gonorrhoeae isolates one
CFM-R isolate (MIC = 0.25 mg/L), which is the first
CFM-R isolate ever described, and one CFM-DS isolate
(MIC = 0.125 mg/L), were identified. No CFM-R/DS iso-
lates were found in 1996. However, from 1997 (one
CFM-R isolate with MIC = 0.25 mg/L) and onwards, the
prevalence of CFM-R and CFM-DS isolates significantly
increased, with the peak resistance level in 2002, where
57.1 % of the examined isolates were CFM-R. The first
isolate with CRO-DS was identified in 2000. CRO-DS
isolates were subsequently found annually in 2001–2005,
with a peak prevalence of 29.1 % in 2003 (Table 3).
penA (encoding PBP 2) sequences of CFM-R/DS Neisseria
gonorrhoeae isolates in Japan
The CFM-R isolate from 1995 was not possible to re-
cover. However, the CFM-DS isolate from 1995 con-
tained the non-mosaic PBP 2 XIII [7, 25], whereas the
CFM-R isolate from 1997 possessed the mosaic PBP 2 X
[3, 7, 13]. These two isolates from 1995 to 1997 were
considered the original CFM-R/DS isolates in the
present study.
Among the CFM-R and CFM-DS isolates from 1998
to 2005 (n = 166), 149 (90 %) isolates were possible to
analyse genetically; of these 149, 12 PBP 2 amino acid
sequence variants were found. Nine were mosaic PBP 2
and three were non-mosaic PBP 2 sequence variants
(VII, XI, XIII). The most prevalent sequence type was
the mosaic PBP 2 X (86.6 %, 129/149). The additionally
identified mosaic PBP 2 sequence variants were variants
of X, i.e. with single amino acid substitutions (XXIV,
XXX, XXXI), XXVI, XXXIV, and three XXXIV variants
with single amino acid substitutions (Fig. 1). Most note-
worthy, the first CFM-DS isolates with the mosaic PBP 2
XXXIV (n = 2) were identified already in 2001. All the
non-mosaic PBP 2 sequence variants contained the
A501V alteration and additionally alterations in G542 or
P551 (Fig. 1, Table 4).
Table 1 New multi-locus sequence typing (MLST) sequence types (STs) identified in this study
MLST ST abcZ adk aroE fumC gdh pdhC pgm Representative strain
Strain name Isolated year
10622 59 39 67 156 149 153 133 NG9837 1998
10623 59 39 67 111 682a 153 133 NG9845 1998
10624 59 39 67 111 150 153 133 NG9930 1999
10625 109 39 170 156 150 71 65 NG9931 1999
10626 126 39 67 159 149 154 65 NG9943 1999
10627 109 39 67 156 149 71 65 NG9942 1999
10628 59 39 170 159 188 71 65 NG9934 1999
10629 660a 39 170 78 147 153 65 NG9918 1999
10630 660a 39 67 78 147 153 65 NG9919 1999
10631 109 39 170 111 152 153 65 NG0168 2001
10632 109 39 170 156 188 153 65 NG0177 2001
10633 126 39 170 78 147 153 65 NG0121 2001
10634 59 39 67 78 149 153 65 NG0157 2001
11052 59 39 754a 78 148 153 65 NG0330 2003
aNew alleles
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MLST analysis of CFM-R/DS Neisseria gonorrhoeae isolates
in Japan
The CFM-DS isolate from 1995, with the non-mosaic
PBP 2 XIII [7, 25], was assigned to MLST ST7365,
whereas the CFM-R isolate from 1997 (mosaic PBP 2 X
[3, 7, 13]) belonged to MLST ST7363.
In total, 370 isolates from 1998 to 2005 (only CFM-R/DS
isolates from 2003 to 2005) were analysed using MLST; all
CFM-R/DS isolates are summarised in Table 4. As shown
in Fig. 2, among all isolates 52 MLST types were revealed
(diversity index = 0.825). Despite that the CFM-R/DS iso-
lates belonged to 17 MLST STs, the diversity index of the
CFM-R/DS isolates (DI = 0.539) was substantially lower
than that of CFM-S isolates (DI = 0.901).
During 1998–2002, MLST ST7363 was the most preva-
lent ST in both CFM-S (40/221, 19.9 %) and CFM-R/DS
strains (53/73, 72.6 %), but the proportion was signifi-
cantly higher in the CFM-R/DS isolates (P < 0.01). During
2003–2005, 61.3 % (46/76) of the CFM-R/DS isolates were
assigned as MLST ST7363. During 1998–2005, all except
six CFM-R/DS ST7363 isolates possessed the mosaic PBP
2 X. The remaining six isolates contained the mosaic PBP
2 XXXIV (n = 3), XXX (X-A501V; n = 2) and XXXIV-
A486V (n = 1), indicating an evolution of PBP 2 X or that
the new PBP 2 mosaic structures developed during the
dissemination of the CFM-R/DS ST7363 strains. However,
Table 2 New Neisseria gonorrhoeae multiantigen sequence
typing (NG-MAST) sequence types (STs) identified in this study
NG-MAST porB tbpB Representative strain
Strain name Isolated year
9027 2494 856 NG9858 1998
9028 1056 241 NG9850 1998
9029 3599 241 NG9860 1998
9030 916 241 NG9870 1998
9031 2296 24 NG9874 1998
9032 4424 10 NG9816 1998
9033 854 10 NG9880 1998
9034 2742 4 NG9882 1998
9035 3986 361 NG9883 1998
9036 4226 10 NG9828 1998
9038 161 137 NG9845 1998
9039 5349a 241 NG0177 2001
9040 5347a 10 NG0178 2001
9041 5348a 241 NG0173 2001
9042 5350a 241 NG0174 2001
9043 5346a 110 NG0115 2001
9044 444 873 NG0216 2002
9045 566 27 NG0211 2002
9046 673 32 NG0214 2002
11434 2461 19 NG0346 2003
11436 5186 113 NG0469 2004
11437 2522 113 NG0467 2004
11438 4260 10 NG0460 2004
11439 6705a 10 NG0324 2003
11440 6710a 10 NG0325 2003
11441 6718a 10 NG0327 2003
11442 6716a 10 NG0328 2003
11443 6712a 10 NG0330 2003
11444 6715a 10 NG0334 2003
11445 6701a 110 NG0335 2003
11446 6706a 21 NG0340 2003
11447 6707a 276 NG0342 2003
11448 6699a 10 NG0344 2003
11449 6702a 10 NG0353 2003
11450 6704a 4 NG0425 2004
11451 6700a 29 NG0426 2004
11452 6714a 110 NG0435 2004
11453 6708a 10 NG0437 2004
11454 6703a 10 NG0440 2004
11455 6717a 110 NG0442 2004
11456 6709a 10 NG0448 2004
Table 2 New Neisseria gonorrhoeae multiantigen sequence
typing (NG-MAST) sequence types (STs) identified in this study
(Continued)
11457 6713a 241 NG0465 2004
11458 6711a 29 NG0466 2004
aNew alleles
Table 3 Resistance and decreased susceptibility to cefixime
(CFM) or ceftriaxone (CRO) in Neisseria gonorrhoeae isolates
cultured from 1995 to 2005 in Kanagawa area, Japan
Year Number of isolatesa CFM-DSa,b CFM-Ra,c CRO-DSa,b
No.a % No.a % No.a %
1995 34 (1) 1 (1) 2.9 1 (0) 2.9 0 0
1996 70 (0) 0 0 0 0 0 0
1997 88 (1) 0 0 1 (1) 1.1 0 0
1998 89 (84) 0 0 5 (5) 5.6 0 0
1999 69 (50) 2 (2) 2.9 3 (3) 4.3 0 0
2000 54 (49) 6 (5) 11.1 6 (5) 11.1 1 (1) 1.9
2001 102 (90) 10 (9) 9.8 34 (32) 33.3 17 (17) 16.7
2002 21 (21) 0 0 12 (12) 57.1 4 (4) 19.0
2003 55 (27) 5 (4) 9.1 26 (23) 47.3 16 (14) 29.1
2004 74 (34) 10 (10) 13.5 29 (24) 39.2 16 (13) 21.6
2005 34 (15) 8 (6) 23.5 10 (9) 29.4 5 (5) 14.7
aNumber of isolates examined genetically is given in parentheses
bMIC = 0.125 mg/L of cefixime or ceftriaxone
cMIC > 0.125 mg/L of cefixime
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50 of the CFM-R/DS isolates were assigned as other
MLST STs (n = 16) than ST7363. Six of these 16 MLST
STs (ST1596, ST1600, ST7356, ST7827, ST10634 and
ST11052) identified in 19 isolates were single locus vari-
ants of ST7363. All these 19 isolates had the mosaic PBP
2 X. Another putative MLST ST cluster that included
CFM-R/DS isolates consisted of ST1579 (n = 1), ST1901
(n = 14), ST8153 (n = 1) and ST10631 (n = 1), which dif-
fered from ST7363 at 2, 3, 4 and 4 loci, respectively, sug-
gesting that ST1901 and its single locus variants ST1579,
ST8153 and ST10631 belong to a genetically different
group from ST7363. Nevertheless, 12 (71 %) of these 17
isolates also possessed the mosaic PBP 2 X. Particularly
noteworthy is that the proportion of MLST ST1901 iso-
lates among the CFM-R/DS isolates significantly increased
from 2.6 % (2/78) in 1998–2002 to 15.8 % (12/76) in
2003–2005. Furthermore, during 2003–2005, all three iso-
lates possessing XXXIV or XXXIV-related PBP 2 se-
quences were assigned to MLST ST1901 (Table 4). One of
these isolates (from 2003) was also assigned as NG-MAST
Fig. 1 Neisseria gonorrhoeae penicillin-binding protein 2 (PBP 2) amino acid sequences in strains with resistance or decreased susceptible to
cefixime. a The dendrogram analysis of amino acid sequences included 12 PBP 2 sequences from N. gonorrhoeae with resistance and decreased
susceptibility to cefixime and a wild-type (WT) PBP 2 sequence (M32091). Lower half contains the wild-type PBP 2 sequence and amino acid
alterations in the non-mosaic PBP2 XI, XIII and VII, which possessed two amino acid substitutions compared to WT. Upper half displays the mosaic
PBP 2 X, XXXI and XXXIV and their single amino acid variants that were found in this study. The numbers of isolates in this study are shown in
parentheses. b Amino acid sequence similarities of mosaic PBP 2 (X, XXXIV and XXVI) and WT are shown. The boundary of N- and C-terminal
domain is from the crystal structure of PBP 2 derived from the penicillin-resistant strain FA19 [33]. The N-terminal domain (1–239) of the mosaic
PBP 2 sequences are similar to WT (over 96.7 %), but the C-terminal domains of mosaic PBP 2 show lower similarity: 86.4 % for PBP 2 X and PBP 2
XXXIV and 87.7 % for XXVI compared to WT. PBP 2 X is identical to PBP 2 XXXIV, except for the C-terminal end (549–582, where seven amino
acids differ). The C-terminal end of PBP 2 XXXIV is identical with that of WT, whereas that of PBP 2 X is identical to PBP 2 XXVI, although the
C-terminal domain of PBP 2 XXVI differs from the mosaic PBP 2 X and XXXIV (97.7 % identity). For detailed amino acid sequences of these and
other PBP 2’s, see Ohnishi et al. [7]
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ST1407 (porB908 and tbp110). This is the first isolate de-
scribed worldwide of this MDR clone that has subse-
quently accounted for most of the reported ESC
resistance globally [3, 4, 8, 9, 12, 14, 15, 24, 26].
NG-MAST analysis of CFM-R/DS Neisseria gonorrhoeae
isolates in Japan
As described above, isolates assigned as MLST ST7363
and containing the mosaic PBP 2 X were predominant
among the CFM-R/DS isolates from 1998 to 2005. To
further investigate the clonality of all the CFM-R/DS
strains from 1995 to 2005 NG-MAST analysis was ap-
plied for the same 372 isolates (only CFM-R/DS isolates
from 2003 to 2005). NG-MAST analysis revealed 194
STs and a high DI (0.988). Eighty-seven STs were identi-
fied among the CFM-R/DS isolates (DI: 0.976), showing
that the CFM-R/DS strains have further evolved.
The CFM-DS isolate from 1995 was assigned as the
NG-MAST ST4045 (porB2445 and tbpB29), which was
not subsequently identified during 1997–2005. The
CFM-R isolate from 1997 belonged to the NG-MAST
ST4127 (porB2520 and tbpB10), which two CFM-R iso-
lates were also assigned to in 1998. However, ST4127
isolates, even isolates with porB2520, were not found
after 1998.
To describe to a great extent the evolution of the iso-
lates examined in the present study the porB gene se-
quences in isolates from 1998 to 2005 (only CFM-R/DS
isolates from 2003 to 2005; n = 370) were compared
(Fig. 3). For comparison, the six major porB alleles from
isolates cultured in Kyoto and Osaka from 2010 to 2012
(porB4, porB206, porB908, porB1059, porB1785 and
porB2569) [24] and porB254 and porB628, which were
reported in CFM-R isolates in Sweden and the USA in
2002 and 2003 [27], respectively, were also included in
the analysis (Fig. 3). Of these eight porB alleles, four of
the porB alleles from the Kyoto and Osaka collection
(porB4, porB206, porB908, porB1059) were also found in
the present study. Seven clusters were generated by the
porB sequences: clusters (CL) A-1, A-2, A-3, B-1, B-2, C
and D (Fig. 3; Table 5). The CL A-1 cluster was the lar-
gest cluster, containing 56 porB alleles from 132 isolates.
The CL A-1 cluster included porB2520, which was from
the first putative CFM-R isolates found in 1997 and
1998. Sixty-six (66.7 %) of the 99 MLST ST7363 CFM-
R/DS isolates from 1998 to 2005 had one of the CL A-1
porB sequences and 64 (64.6 %) had the mosaic PBP 2
X. Furthermore, 64.5 % (49/76) of all the CFM-R/DS iso-
lates from 2003 to 2005 belonged to the CL A-1 cluster.
As mentioned above, the CFM-R/DS isolates with
porB2520 from 1997 to 1998 did not appear to be widely
disseminated. Instead, isolates with other porB sequences,
such as porB1059, porB917 and porB206 in the CL A-1
cluster, appeared to become dominant (Fig. 3).
The CL B-2 cluster contained 21 porB gene sequences.
porB2465, found in three CFM-R isolates in 1998,
belonged to this porB sequence cluster. In 1998–2002,
18 (34.0 %) of the 53 CFM-R/DS MLST ST7363 isolates
Table 4 Multilocus sequence typing (MLST) and penicillin-binding protein 2 (PBP 2) variants [7] in Neisseria gonorrhoeae isolates
(n = 149) cultured from 1998 to 2005 (only isolates with resistance or decreased susceptibility to cefixime) in Kanagawa area, Japan
PBP 2 X family PBP 2 XXXIV family
MLST n = X + E101D (XXIV) + A501V (XXX) + A532V (XXXI) XXXIV + P551L (XXXII) +A486V + P551Q XXVI VII XI XIII
7363 99 93 2 3 1
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had porB gene sequences in the CL B-2 cluster. How-
ever, in 2003–2005 only two (4.3 %) of the 46 CFM-R/
DS MLST ST7363 isolates belonged to the CL B-2 porB
sequence cluster. In contrast to the CFM-R/DS MLST
ST7363 isolates, porB sequences from non-ST7363
CFM-R/DS isolates with the mosaic PBP 2 X were found
in all seven porB sequence clusters (Fig. 3).
Among the CFM-R/DS isolates with PBP 2 non-X se-
quence variants, isolates with the non-mosaic PBP 2 VII,
XI and XIII possessed porB2468 in CL A-1, porB822 in
CL E and porB6704 in CL A-2, respectively. Four
isolates with mosaic PBP 2 X-like sequence variants
(XXIV (n = 1), XXX (n = 2) and XXXI (n = 1)) had three
porB alleles: porB908 (CL B-1), porB709 (CL A-1) and
porB2467 (CL A-2), respectively. All seven CFM-R/DS
isolates with the mosaic PBP 2 XXXIV, which is now the
most prevalent mosaic PBP 2 sequence variant in CFM-
R/DS isolates globally [3, 4, 8, 9, 12, 24, 26], or XXXIV-
like sequence variants possessed porB alleles in the CL
B-1, i.e. porB908 (n = 5), porB2516 (n = 1) and porB2513
(n = 1). Among five CFM R/DS isolates possessing PBP 2
XXXIV or its relative with porB908, four belonged to
Fig. 2 Molecular epidemiological relatedness of Neisseria gonorrhoeae isolates from 1998 to 2005 in the Kanagawa area, Japan. Minimal spanning
tree of 48 MLST STs shows genetic distance of STs derived from 370 isolates. Circle sizes denote the number of isolates sharing the same ST.
Black indicates N. gonorrhoeae isolates with resistance or decreased susceptibility to cefixime
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MLST ST7363. However, most noteworthy is that the
remaining isolate was assigned as MLST ST1901 and
NG-MAST ST1407 (porB908 and tbpB110) and con-
tained the PBP 2 XXXIV with an additional P551Q mu-
tation. The por908 was, in general, the major porB of
CFM-R/DS isolates belonging to the MLST ST1901. The
MDR N. gonorrhoeae clone MLST ST1901, NG-MAST
ST1407 with a PBP 2 mosaic XXXIV has accounted for
most of the ESC resistance globally during the recent
decade [3, 4, 8, 9, 12, 24, 26] and this clone has also shown
its capacity to develop high-level ceftriaxone resistance,
i.e., develop into a superbug such as F89 [14, 15].
Discussion
Gonorrhoea and the high level of antimicrobial resist-
ance in N. gonorrhoeae represent major public health
concerns globally [1–6]. Treatment failures with the
ESCs, the last remaining options for first-line empirical
monotherapy of gonorrhoea, have been reported in sev-
eral countries [3, 4, 7–12]. Most of these ESC treatment
failures have been caused by MDR N. gonorrhoeae
strains belonging to the MLST ST7363 and ST1901
[3, 4, 7, 9, 12, 13]. Among the ESC-resistant MLST
ST1901 gonococcal strains, isolates assigned as the NG-
MAST ST1407 have been the most frequent worldwide
[3, 4, 8, 9, 12], and this clone has also shown its capacity
to develop high-level ceftriaxone resistance, i.e., develop
into a superbug such as F89 [14, 15].
In the present study the initial emergence and dissem-
ination of these internationally transmitted ESC-
resistant gonococcal clones in Japan from 1995 to 2005
were investigated. We showed that the first CFM-R iso-
late was cultured as early as 1995 in the Kanagawa area,
Japan, which is four years earlier than previously re-
corded. This CFM-R isolate (MIC = 0.25 mg/L) pos-
sessed a non-mosaic PBP 2 XIII sequence variant [7, 25],
with the amino acid alterations A501V and P551S that
increase the ESC MICs [3, 4, 24, 28, 29]. This first CFM-
R strain did not appear to spread widely; however, two
years later (in 1997) one CFM-R MLST ST7363 isolate
with the mosaic PBP 2 X [3, 7, 13] was found. During
1998–2002, this was the predominant CFM-R/DS strain
type in the Kanagawa area, which is a neighbouring area of
Tokyo. In contrast, in 1998–2002 MLST ST1901 isolates
accounted for 11 % (32/294) of the isolates, but only two
were CFM-R. Furthermore, no isolate was typed as NG-
MAST ST1407 and the two CFM-R MLST ST1901 iso-
lates possessed the mosaic PBP 2 X, and not the nowadays
frequent mosaic PBP 2 XXXIV [3, 4, 8, 9, 12, 24, 26].
This observation indicates that the CFM-R/DS MLST
ST1901 clone(s) were originally possessing the mosaic
PBP 2 X, which possibly was originally transferred
from the MLST ST7363 strains spreading widely, and
subsequently, acquired the mosaic PBP 2 XXXIV that
presently is the most frequent PBP 2 sequence variant
in ESC-R/DS MLST ST1901 and NG-MAST ST1407
isolates [3, 4, 8, 9, 12, 24, 26]. In the present study it
was also shown that the first MLST ST1901 and NG-
MAST ST1407 isolate was cultured already in 2003.
This is substantially earlier than the previously first
described NG-MAST ST1407 strain, which possessed
the mosaic PBP 2 XXXIV, identified in the USA in
2008 [30]. Since then, this strain type has been found
to account for most of the ESC-R/DS isolates globally
[3, 4, 8, 9, 12, 24, 26] and this clone has also shown
Table 5 Penicillin-binding protein 2 (PBP 2) [7] and porB gene
sequence cluster (A1-D) in Neisseria gonorrhoeae isolates (n = 149)
cultured from 1998 to 2005 (only isolates with resistance or
decreased susceptibility to cefixime in 2002–2005) in Kanagawa
area, Japan
PBP 2 (2003–2005, n = 76a) A1 A2 A3 B1 B2 C D
X X (62) 41 9 0 4 4 2 2
+ E101D (XXIV) (1) 1
+ A501V (XXX) (2) 2
XXXIV XXXIV (1) 1
+ P551L (XXXII) (2) 2
+ P551Q (1) 1
- XXVI (6) 6
PBP 2 (1998–2002, n = 73b) A1 A2 A3 B1 B2 C D
X X (67) 33 3 2 1 27 1 0
+ A532V (XXXI) (1) 1
XXXIV XXXIV (2) 2
+ A486V (1) 1
aOne isolate possessed the non-mosaic PBP 2 XIII [7]. The porB sequence from
this isolate belonged to the cluster A2
bTwo isolates possessed the non-mosaic PBP 2 VII and XI [7]
(See figure on previous page.)
Fig. 3 Comparison of the porB gene sequences in Neisseria gonorrhoeae isolates obtained from 1998 to 2005 in the Kanagawa area, Japan.
Dendrogram was constructed using 163 partial porB sequences (490 bp) by UPGMA. One -hundred -fifty-nine porB sequences were from N.
gonorrhoeae isolates examined in this study, including four of the major porB alleles in the Kyoto/Osaka strains isolated during 2010–2012 [24],
(depicted in the shaded frame). The two remaining of the major porB alleles in the Kyoto/Osaka strains (porB1785 and porB2569) [24] and porB254
and porB628, from strains with cefixime resistance in Sweden (2002) and the USA (2003) [27], were also included with the porB type
framed. Each box illustrates an individual strain. When more than four isolates with the identical porB type were cultured in the same
year, the number of isolates is shown. Red and black boxes indicate MLST ST7363 strains and non-ST7363, respectively. Filled boxes
indicate CFM-R/DS strains. Red and black filled rectangles, ST7363 and non-ST7363 strains with PBP 2 X, pink and gray are mosaic PBP 2
other than PBP 2 X and non-mosaic PBP 2
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its capacity to develop high-level ceftriaxone resistance,
i.e., develop into a superbug such as F89 [14, 15]. All 11
CFM-R/DS isolates from 1997 to 1999 were assigned to
MLST ST7363 (mosaic PBP 2 X), but the NG-MAST ana-
lysis revealed two major types of CFM-R/DS isolates, i.e.
due to the diversification of the porB gene (porB2520 in
CL A-1 and porB2465 in CL B-2). These two clones were
considered to have emerged and started to disseminate in
the Metropolitan area, including Kanagawa. Introduction
from some other area(s) was highly unlikely because there
is no recorded isolation of CFM-R gonococcal strains be-
fore 1999 in any other place. The reasons for the initial
emergence of ESC-resistance in Kanagawa and in general
gonococcal antimicrobial resistance in Japan have still not
been completely resolved, however, they have been hy-
pothesized elsewhere [3].
In general, during 1998–2002, the MLST ST7363
(31.6 %), ST7359 (13.9 %) and ST1901 (10.9 %) were the
three most prevalent STs. During 2003–2005, the pro-
portion of MLST ST1901 strains significantly increased,
particularly among the CFM-R/DS isolates (from 2.6 %
to 15.8 % of isolates). According to a recent study from
2012–2012 [24], these three MLST STs have remained
the most prevalent MLST STs in the Kyoto/Osaka area;
however, ST1901 has taken over as the significantly most
prevalent ST (ST1901: 40.9 %, ST7359: 19.2 % and
ST7363: 17.1 %). In the present study all 41 ST7359 iso-
lates possessed NG-MAST tbpB241 and 90.2 % con-
tained a porB sequence in CL C-1, including porB2569,
which was also the major allele among the MLST
ST7359 Kyoto/Osaka strains in 2010–2012 [24]. Accord-
ingly, MLST ST7359 strains have also been frequently
isolated in many years. However, these strains have been
highly susceptible to CFM and initially to also ciprofloxa-
cin. In contrast, a major proportion of the MLST ST7363
and ST1901 strains have also been resistant to ciprofloxa-
cin for decades. It is not evident whether CFM-R/DS ac-
quired the ciprofloxacin-R phenotype, or vice versa, but
these types of MDR strains had significant advantages,
and accordingly, could rapidly and efficiently be dissemi-
nated, first locally in Japan and then globally.
Conclusions
The two main internationally spread cefixime-resistant
gonococcal clones, MLST ST7363 and ST1901 (NG-
MAST ST1407 most frequent internationally) that also
have shown their capacity to develop high-level ceftriax-
one resistance (superbugs H041 and F89 [7, 14, 15]),
likely emerged, started to disseminate and evolved in the
metropolitan area, including Kanagawa, in Japan, which
was followed by global transmission. A grave concern is
that we might face a similar scenario in the future, i.e.
that strains with resistance to both ceftriaxone and azi-
thromycin, which are today used widely internationally
in dual antimicrobial treatment regimens [31, 32], start
to spread. It is crucial to understand the emergence and
spread of ESC- and MDR-resistant gonococcal strains
globally to develop and implement evidence-based strat-
egies for prevention and control of gonorrhoea.
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